2020 American Transplant Congress
Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients
*Purpose: The purpose of the study was to describe the patterns of use and clinical/virologic outcomes of letermovir treatment for established CMV infection in transplant…2020 American Transplant Congress
The Effect of Undernutrition and Immunosuppression on Cytomegalovirus Specific T Cell Responses
1Pediatrics, Duke University, Durham, NC, 2Surgery, Duke University, Durham, NC
*Purpose: Cytomegalovirus (CMV) infection remains a significant issue in transplantation, especially in those who are undernourished. While undernutrition is associated with impaired T cell immunity…2020 American Transplant Congress
Clinical and Laboratory Characteristics of Early and Late-Onset Cytomegalovirus Infection Following Universal Prophylaxis in Kidney Transplant Recipients
University of California, San Francisco, San Francisco, CA
*Purpose: Cytomegalovirus (CMV) is the most important viral infection in organ recipients and can cause life-threatening infections, compromising long-term graft function. Most transplant centers use…2020 American Transplant Congress
An OPO’s Experience in Increasing Transplantation with the Hope Project
*Purpose: The purpose of this report is to describe one OPO’s experience in participating in the Hope Project. This research project is designed to evaluate…2020 American Transplant Congress
Preemptive Direct Acting Antiviral Therapy as Prophylaxis in Donor HCV-Positive to Recipient HCV-Negative Solid Organ Transplant: a Comprehensive Review
Gastroenterology, Louisiana State University of Health Sciences Shreveport, Shreveport, LA
*Purpose: With the advent of highly effective and safe oral Direct acting Antiviral agents (DAAs), several transplant centers have adopted protocols for using HCV positive…2020 American Transplant Congress
Cytomegalovirus Infection and Outcomes in Pancreas Transplant Recipients in the Prophylaxis Era
1UW Health, Madison, WI, 2UWMF, Madison, WI
*Purpose: Evaluate epidemiology and outcomes of cytomegalovirus infection (CMV) in pancreas transplant recipients (PTR) in the current era of valganciclovir (VGC) prophylaxis (PPX)*Methods: Adult PTRs…2019 American Transplant Congress
Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk
*Purpose: According to recent guidelines ganciclovir or valganciclovir chemoprophylaxis is recommended for all kidney transplantation (KT) recipients (except for D-/R- serology) for preventing cytomegalovirus (CMV)…2019 American Transplant Congress
The Natural History and Time to Seroconversion of CMV in the Era of Post-Transplantation Chemoprophylaxis: A Single Center Study
Division of Infectious Diseases, University of Arizona, Tucson, AZ
*Purpose: The current cytomegalovirus (CMV) guidelines in solid organ transplantation recommend chemoprophylaxis (ppx) in post-kidney transplantation recipients. This approach has led to a reduction in…2019 American Transplant Congress
Cidofovir for BK Nephropathy Rescue Treatment: A Single Center Experience
*Purpose: Cidofovir is a potentially nephrotoxic antiviral drug used primarily as a treatment for CMV retinitis however due to its potent antiviral effects has been…2019 American Transplant Congress
Protocol Cidofovir for Refractory Polyomavirus Associated Nephropathy in Kidney Transplant Recipients
University of Maryland Medical Center, Baltimore, MD
*Purpose: Dose-limiting nephrotoxicity has historically precluded the use of cidofovir for polyomavirus associated nephropathy (PVAN). With incidence of BK viremia in kidney transplant recipients increasing…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »